Fmoc-leucine

Fmoc-Leucine (N-FMOC-leucine) is an anti-inflammatory agent that not only promotes extracellular Ca²⁺ influx but also facilitates intracellular Ca²⁺ release. Fmoc-Leucine is a selective ligand for PPARγ (K_i = 15 μM), exhibiting insulin-sensitizing effects but with weak fatogenic activity. Fmoc-Leucine exhibits unique self-assembly properties and can form transient gels, stable gels, or crystals/2D sheets through different pathways. Fmoc-Leucine can be used in the research of diabetes, colitis, and bladder cancer^[1][2][3][4]. In Vitro:Fmoc-Leucine (1 mM, 24 h) significantly enhances the interaction between PPARγ and SRC-1 in RK13 cells^[1].
Fmoc-Leucine (10 μM, 0-6 d) induces the expression of LPL and aP2 in 3T3-L1 cells, but its ability to accumulate lipids is significantly lower than that of Rosiglitazone (HY-17386)^[1].
Fmoc-Leucine (0.1-2 mM) rapidly and continuously increases [Ca²⁺]i in MDCK and BFTC cells in a concentration-dependent manner with an EC₅₀ in MDCK cells of 0.5 mM^[3][4].
Fmoc-Leucine induces the release of Ca²⁺ from the endoplasmic reticulum and activated the influx of Ca²⁺ in BFTC bladder cancer cells^[4].
In Vivo:Fmoc-Leucine (10-60 mg/kg, i.p., once daily for 7 or 14 days) improves mice glucose tolerance in both normal and diet-induced insulin resistance and diabetes models, and has a synergistic effect with Rosiglitazone^[1].
Fmoc-Leucine (50 mg/kg, i.p., once daily for 4 days) reduces the severity of TNBS-induced colitis in the mice^[1].